Todd Carter, PhD (CSO at Voyager Therapeutics) talks with incoming Communications Committee Chair Lynnea Olivarez about changes in the approach to developing gene therapies for CNS disorders like Huntington's disease.
Show your support for ASGCT!: https://asgct.org/membership/donate
See omnystudio.com/listener for privacy information.
